Allergy Immunotherapy
Total Trials
1
As Lead Sponsor
0
As Collaborator
Total Enrollment
16
NCT06831812
Phase I Clinical Study of AV-1959R: Abeta-targeting Anti-Alzheimer's Vaccine
Phase: Phase 1
Role: Collaborator
Start: Jun 12, 2024
Completion: Oct 31, 2025
Loading map...